BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25635758)

  • 1. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
    Ustun C; Marcucci G
    Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core binding factor acute myeloid leukemia.
    Paschka P
    Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
    Solh M; Yohe S; Weisdorf D; Ustun C
    Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
    Marcucci G; Caligiuri MA; Bloomfield CD
    Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
    Mrózek K; Bloomfield CD
    J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core-binding factor acute myeloid leukemia.
    Sangle NA; Perkins SL
    Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
    J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.
    Duployez N; Willekens C; Marceau-Renaut A; Boudry-Labis E; Preudhomme C
    Expert Rev Hematol; 2015 Feb; 8(1):43-56. PubMed ID: 25348871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
    Panigrahi C; Tikare N; Das PK; Padhi S
    BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
    Borthakur G; Kantarjian H
    Blood Cancer J; 2021 Jun; 11(6):114. PubMed ID: 34135311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
    Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
    Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
    Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
    Dombret H; Preudhomme C; Boissel N
    Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
    Pigazzi M; Manara E; Buldini B; Beqiri V; Bisio V; Tregnago C; Rondelli R; Masetti R; Putti MC; Fagioli F; Rizzari C; Pession A; Locatelli F; Basso G
    Haematologica; 2015 Mar; 100(3):e99-101. PubMed ID: 25480496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.